The diagnosis of asthma is currently based on clinical history, physical examination and lung function, and to date, there are no accurate objective tests either to confirm the diagnosis or to discriminate between different types of asthma. This consensus exercise reviews the state of the art in asthma diagnosis to identify opportunities for future investment based on the likelihood of their successful development, potential for widespread adoption and their perceived impact on asthma patients. Using a two-stage e-Delphi process and a summarizing workshop, a group of European asthma experts including health professionals, researchers, people with asthma and industry representatives ranked the potential impact of research investment in each technique or tool for asthma diagnosis and monitoring. After a systematic review of the literature, 21 statements were extracted and were subject of the two-stage Delphi process. Eleven statements were scored 3 or more and were further discussed and ranked in a face-to-face workshop. The three most important diagnostic/predictive tools ranked were as follows: "New biological markers of asthma (eg genomics, proteomics and metabolomics) as a tool for diagnosis and/or monitoring," "Prediction EARIP members are present in Appendix 1.
of future asthma in preschool children with reasonable accuracy" and "Tools to measure volatile organic compounds (VOCs) in exhaled breath."
| INTRODUCTION
The European Commission launched the European Innovative Partnerships (EIPs) in the FP7 program as a way of shortening the process from the initiation of research to the marketing of the findings, whenever possible, in all kinds of fields. According to the EU Commission, "EIPs act across the whole research and innovation chain, bringing together all relevant actors at EU, national and regional levels to: (1) step up research and development efforts; (2) coordinate investments in demonstration and pilots; (3) anticipate and fast-track any necessary regulation and standards; and (4) mobilize 'demand' in particular through better coordinated public procurement to ensure that any breakthroughs are quickly brought to market." In accord with this philosophy, Asthma UK applied for an EIP for asthma and constituted the European Asthma Research Innovative Partnership (EARIP) with the aim of producing a European roadmap to quickly, effectively and drastically reduce asthma morbidity and mortality, and to look for the eventual prevention and cure of asthma.
Led by Asthma UK, EARIP gathered a considerable number of stakeholders from health professionals, patient associations and pharmaceutical companies. The project was divided into different work packages, including one on diagnostic tools. In the present consensus statement, we present the asthma diagnostic tools on which stakeholders agreed warranted the future investment.
The group, with external consultation, agreed on a list of relevant topics (Table 1) , which constitute the different topics of the systematic review presented wherein. Working group members performed literature searches based on expertise and knowledge in this area (Table S1 ). The framework shown in Table 2 was applied to each topic in order to perform a short and focused review, providing upto-date, in-depth information on each topic, to provide the base for consensus prioritization and ranking. Is it a useful tool to diagnose/follow up asthma?
Should it be part-currently and in the near future-of the diagnosis/follow-up of asthma in every case and age?
Is it suitable for point of care detections?
Will it enable self-evaluation and follow-up of patients?
What the future would be with respect to the specific tool? Do you expect further advances here? If so, which ones?
If you expect several advances, please state the one most important in your opinion GARCIA-MARCOS ET AL.
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Several diagnostic tests exist the sensitivity and specificity of which are not as high as would be desired, and thus, diagnosis can be considered a mosaic of many pieces including tests of lung function, tests for inflammatory markers and patterns of characteristic symptoms and signs in a clinical history. A further problem is the lack of standardization of existing diagnostic tests and in particular their applicability or even usability in young children.
As we become more knowledgeable about the different asthma phenotypes, there is a desperate need for new diagnostic tools to prevent over-, under-diagnosis and over-, under-treatment of patients to reduce asthma morbidity and mortality. 
Eosinophils and eosinophil cationic protein
Eosinophils can be easily measured in peripheral blood, but may be of use only when asthma is eosinophilic, which is not necessarily the case, especially in adult patients. Blood eosinophils >4% increase the probability that recurrent wheeze in combination with other risk factors in a child is asthma. 2 Although being significant, the correlation between blood and sputum eosinophils is far from perfect. 3 Setting the abnormal threshold of blood and sputum eosinophils at 400/lL and 3%, respectively, a discrepancy was found in 32% in a large asthma cohort, the group with high sputum eosinophils but normal blood eosinophil count representing 25% of the patients. 4 Even though studies have confirmed the association of ECP with allergic asthma, ECP determination does not appear to be a valuable diagnostic marker of asthma, as changes in serum ECP concentrations can also be found in other atopic diseases such as allergic rhinitis, and even in conditions not related to allergic inflammation such as bacterial sinusitis. 5 Determination of ECP concentration has been discussed for assessing the severity of asthma, particularly in children, but it has not evolved as a helpful marker of inflammation in clinical practice.
In summary, blood eosinophils may play a role in the diagnosis of eosinophilic asthma and have a value in risk-assessment and response to treatment. In addition, as the correlation between airway eosinophilia and blood eosinophilia is low, the differential role in subendotypes will have to be better defined. There does not seem to be an advantage for measuring ECP compared to the absolute eosinophil count.
Periostin
Periostin appeared to be a good systemic biomarker of Th2-driven or eosinophil airway inflammation in adults. 6 However, expectations about the usefulness of periostin to diagnose asthma have not been fulfilled as it is increased during growth and can be also be elevated in many inflammatory processes. 
| Exhaled breath
Fractional exhaled nitric oxide (FeNO) in asthma diagnosis and monitoring Asthma diagnosis Exhaled nitric oxide is a user-friendly biomarker, which has become increasingly popular among clinicians. While first measured online by chemoluminescence with the fixed machine, it can now be measured with a portable electrochemistry system. As
FeNO value is flow sensitive, it is important to standardize the flow rate at which the measure is performed. It has become accepted that FeNO is best measured at a flow rate of 50 mL/s. 8 Early studies found that patients with asthma displayed raised level of FeNO in their exhaled breath compared to healthy subjects.
Treatment with ICS results in a dramatic reduction in the level of FeNO. 9 Current smoking also causes a sharp reduction in measured values. 10 Median values of FeNO in large asthma cohort studies were found to range between 25 and 35 ppb. 10, 11 Several studies have investigated the use of FeNO to make an asthma diagnosis. A threshold value of 20 ppb combined to symptom was proposed as a tool for asthma diagnosis that was superior to the measurement of the fluctuations of peak expiratory flow rate in mild-to-moderate asthmatics. This threshold was probably too low and more recent studies in patients with symptoms of asthma and normal baseline FEV1 value, or no significant bronchodilation has shown that FeNO threshold of 34 ppb (at the flow rate of 50 mL/s) yielded the best compromise for an asthma diagnosis with a high positive predictive value but a low negative predictive value.
12
While it was initially thought that elevated FeNO was a key marker of asthma in general, it later appeared that FeNO was mainly reflecting the presence of eosinophilic airway inflammation. 10 Therefore, elevated FeNO is assumed to reflect an eosinophilic asthma phenotype, which account for approximately 50% of all asthmatics seen in clinical practice although higher in children. 4, 13, 14 The threshold values that predict eosinophilic inflammation vary according to the dose of ICS, the smoking status and atopy. 10 Combining FeNO and peripheral eosinophil counts seems to be a better approach than just using FeNO values. 15 However, it should be always be kept in mind that asthma cannot be ruled out when symptoms are compatible with the condition despite low values of FeNO, as asthma is not necessarily eosinophilic. 16, 17 Asthma monitoring FeNO has been proposed as a biomarker that may help the clinician to manage asthma. 18, 19 FeNO values above 33 ppb in one study 20 and above 47 ppb in another 21 were found to predict a good clinical response to ICS in patients with chronic respiratory symptoms. This is in line with the observation that only eosinophilic asthma convincingly responds to inhaled corticoids and add to the importance of asthma phenotyping in clinics. 22 The utility of using FeNO to adjust the dose of ICS to reduce exacerbations in asthmatics already receiving treatment has been investigated in several studies with controversial results. 23, 24 In this setting, FeNO seems to perform less well that sputum eosinophils.
However, thresholds to adjust the dose of ICS may not have been chosen adequately in some of those trials. 25 Accuracy of FeNO measurement is firmly established, and it is recognized that elevated value reflects an eosinophilic phenotype and predicts good response to ICS. 18 There is a need to study the cost-effectiveness of FeNO as a tool for asthma diagnosis and choice of treatment in a large-scale cohort study.
Volatile organic compounds
Assessing VOCS using electrosensor (eNose) and, even better, qualifying and measuring them using mass spectrometry has great potential but to date has only been done in a limited series in research settings. 26 This has been done to distinguish asthmatic lungs from those normal ones, but no study has been yet published which has assessed the measurements of VOCs to monitor asthma treatment, although one study used VOCs to predict exacerbations in children with reasonable accuracy. 27 Further exploring the value of VOCS to assist phenotyping asthma and predicting major clinical outcomes such as exacerbations and response to treatment would be of great interest.
Markers in breath condensate
Exhaled breath condensate (EBC) enables the study of the pathological processes undergoing in the lung. 28 As EBC is a non-invasive technique, it can be easily applied even in children too young to be able to perform other tests. In EBC, several molecules have been studied that may have a role as biomarkers in asthma.
Many studies have investigated the role of eicosanoids in asthma.
The presence of these mediators in EBC has been documented using both immunoassays and reference analytical techniques. Increased levels of LTB4, a potent inflammatory mediator, have been demonstrated in steroid na€ ıve children 29 and adults 30 with asthma. Likewise, increased levels of cysteinyl leukotrienes, which are powerful broncho-constrictors and pro-inflammatory mediators, have been reported in both children and adults, with the highest concentrations found in subjects with severe asthma, despite ongoing ICS therapy. 31, 32 Beside leukotrienes, which are 5-lipoxygenase metabolites, increased levels of other inflammatory metabolites of the 15-lipoxygenase pathway such as eoxins, have been reported in asthmatic children. 33 Interestingly, the simultaneous assessment of a set of metabolites of arachidonic acid led to the identification of a profile of eicosanoids (including prostaglandins and leukotrienes) capable of discriminating asthmatic and healthy children with high accuracy. 34 Several markers of oxidative stress have also been studied in EBC, pointing to an increased oxidative burst in asthmatic airways. and it seems sensitive to corticosteroid treatment. 37 Similar results
were found in children. 38 These features suggest a possible role of this biomarker in the follow-up of asthmatic patients. Noteworthy, the measurement of oxidative stress biomarkers in EBC may help in the identification of asthmatic subjects with higher oxidative stress, who may likely benefit from the development of novel anti-oxidant treatments.
Exhaled breath condensate pH is a robust marker, with a good reproducibility. 39, 40 Reduced EBC pH has been reported in both adults and children with asthma. 41 In particular, a significant reduction in PH of the airways has been reported during acute asthma exacerbations. 36, 42, 43 Nonetheless, in the epidemiological setting, EBC pH could not discriminate between asthmatic and healthy subjects. 44 In a large cohort of subjects with severe and non-severe asthma, EBC pH turned out to be on the whole normal, but there was a subgroup of asthmatic subjects with very low EBC pH (<6.5). 45 EBC pH may be a useful biomarker in the characterization of a specific asthma subphenotype.
Increased levels of adenosine have been found in the EBC of asthmatic children and adults. 46 Using multiplex immunoassay technology, increased levels of cytokines, chemokines and soluble adhesion molecules have been reported in children with asthma and also in preschool children found to have persistent wheezing at 5 years of age. [47] [48] [49] Eventually, increased levels of the inflammatory and oxidative stress mediator ADMA (asymmetric dimethylarginine) have been showed in EBC from asthmatic children. 50 The EBC technology has a significant potential for asthma diagnosis and monitoring, but the technique needs to be better standardized if we want to move it from research to clinical practice.
Investments are urgently needed to achieve a full standardization of the methodologies used for sample collection and analysis.
| Sputum and bronchoalveolar lavage
Ideally, any material obtained directly from the lower airways of asthmatic patients could be very useful diagnostic biomarker. A large
number of studies have been conducted over the last decades to evaluate the diagnostic utility of sputum and bronchoalveolar lavage (BAL). Sputum samples collection is not always a simple procedure, especially in children and BAL is an invasive technique.
51,52
Sputum Studies on sputum look mainly at the potential informative role of sputum as a material with airway inflammatory biomarkers. Most studies have focused on asthma severity assessment and provision of more efficient biomarker-guided treatment.
53-55
The technique of induced sputum that allows to collect airway secretion after inhalation of saline is valuable in approximately 80%
of the patients and has been key in the emergence of the concept of inflammatory phenotype. 56 Sputum eosinophil count, neutrophils and several soluble mediators-most recently periostin-have been examined. 54 They are considered as the only non-invasive measure of airway inflammation that has a clearly proven utility in clinical practice in adults. 56 Recent studies have further highlighted the role of sputum eosinophils in poor asthma control. A retrospective study on a large asthma cohort has shown that patients combining sputum eosinophil >3% and blood eosinophil counts >400/lL have poor asthma control and are prone to exacerbate. 4 In a prospective study conducted in severe asthmatics uncontrolled despite high dose of ICS and LABA, the repeated presence of eosinophils in the sputum was associated with increased of excacerbations. 57 Furthermore, in a large retrospective cohort of asthmatics, it has been shown that both fluctuation in FEV1 and fluctuation in sputum in sputum eosinophils independently correlated with change n ACQ6. 58 Sputum induction can be effectively performed in adults, but there might be difficulty in collecting sufficient sputum in children under 8 years. 51, 56 Furthermore, one study in children using sputum eosinophils for monitoring asthma was negative. 53 More studies are needed to clarify the biomarker (or combination of biomarkers) that could be most valuable in practice as a tool in precision medicine.
Bronchoalveolar lavage
BAL is a major tool in the diagnostic procedure for a number of pulmonary diseases, including asthma. It can provide useful information about the pattern of airway inflammation in terms of total cellularity, differential cell profile and several inflammatory mediators. 59, 60 However, the information available is fragmentary, as most of the studies look at either refractory asthma or certain biomarkers from patients in whom bronchoscopy could be justified and suffer from lack of specificity. 59, 61 Subsequently, these studies are affected by methodological difficulties and selection bias, with patients having the sufficiently severe disease to justify an invasive sampling procedure. Data interpretation arising from such studies needs special caution. BAL has also been used for specific asthma phenotypes identification. 61 Because of the invasive nature of fiberoptic bronchoscopy, BAL could be used in certain patients only. It is still useful for difficult asthma to detect other implicated causes of symptoms such as silent aspiration or persistent bacterial infection or congenital abnormalities (children).
| Systems biology
In the study of chronic complex diseases, such as asthma, beside the assessment of individual biomarkers, it is of utmost importance to study several mediators simultaneously, through a systems biology
approach. An overall profile can better mirror the complexity of asthma, in the pathogenesis of which a large number of cell types and molecular pathways contribute, interacting in complex networks.
62,63
The "-omic" technologies (genomics, proteomics and metabolomics) are systems biology platforms. Being guided by no a priori assumptions, they look into which components are associated with a given pathological condition, shedding light on pathogenic pathways and phenotypic characteristics with a hypothesis-generating approach.
63
The "-omic" technologies, proteomics and metabolomics in particular, have been applied in the study of asthma. The proteomic analysis of EBC proved that it is possible to identify profiles of differentially expressed proteins, capable of discriminating asthmatic children from healthy controls. 64 The metabolomics approach has been applied to several biofluids. In adults, the metabolomics analysis of serum 65 and exhaled breath condensate 66 samples demonstrated a clear separation between asthmatic and healthy subjects. Moreover, the metabolomics analysis of urine samples showed that during an acute exacerbation, a profound alteration of the metabolic profile occurs, with a significant role of the metabolites indicative of oxidative stress. 67 In children, metabolomic analysis of both urine and EBC samples proved capable of clearly discriminating between healthy and asthmatic children. 68, 69 Metabolomics has been also applied in the characterization of different asthma phenotypes, and a separate metabolic profile has been demonstrated in children with severe asthma by applying the metabolomics approach either to plasma 70 or to EBC 50 samples.
An "-omic" approach has been applied also to the study of volatile organic compounds (VOCs) in exhaled breath. The VOCs profile could discriminate asthmatic from healthy children. 48 In addition, the study of VOCs profile seems to have promising application for the prediction of asthma exacerbation 27 and for the early identification of asthmatic children among preschool children with recurrent wheezing.
71
The "-omic" technologies may have a key role in the development of personalized medicine, potentially contributing to shift the focus of medicine from the traditional symptom-oriented diagnosis and treatment of diseases (reactive medicine) towards the so-called P4 medicine, which concentrates on preserving health through the prevention and early diagnosis of disease.
72
The "-omic" technologies, in fact, enabling the simultaneous assessment of several mediators can lead to the discovery of early diagnostic profiles and can shed light on new, sometimes unexpected, biomarkers that may be applied to monitor asthma and to guide therapy. 81 and only 10.5% of 3612 asthmatic children having a FEV 1 /FVC < 80%. 82 In this study, FEV1/FVC < 80% had a high sensitivity for asthma diagnosis (>90%) but low specificity (<20%), being associated with asthma diagnosis in a patient with concomitant allergic rhinitis but not in children without allergic rhinitis.
A fixed limit FEV 1 /FVC ratio (<70% in adults) is often used to identify airflow obstruction instead of the lower limit of normal (<5th percentile). 83 This fixed cut-off points have been shown to cause much misidentification of airflow obstruction specially in young adults, increasing the likelihood of under diagnosis of obstruction. 84 The use of Z-scores in children is probably more appropriate.
A decreased FEF 25%-75% is indicative of small airway obstruction.
The utility of an isolated decrease in FEF 25%-75% in the setting of otherwise normal spirometry is unclear, because values are more variables than FEV 1 . Evidence suggests than a reduced FEF 25%-75%
correlates with bronchial hyperresponsiveness on bronchoprovocation testing. 85, 86 The utility and limitations of spirometry in asthma diagnosis are well established. A wider use of this technique in primary care with the implementation of new algorithms will allow a better diagnostic classification of both paediatrics and adult patients. However, there is no single randomized control trial showing that guiding treatment on FEV1 improves asthma outcomes.
Plethysmography and asthma diagnosis
Plethysmograhic measurement of lung volumes does not provide much additional information for clinical decision-making in most patients with asthma, and it is not recommended in current guidelines.
Lung hyperinflation is frequent in uncontrolled asthma, and a significant proportion of both children and adult asthmatic patients have elevated residual volume and abnormal RV/TLC ratio in the presence of normal FEV 1 /FVC ratio and the absence of significant bronchodilator response. 87, 88 The clinical significance of these findings in asthma needs further prospective studies. In adults, the role of airway resistance (Raw) and specific airway conductance (sGAW)
as an aid to asthma diagnosis has been explored in a real-life study and found to predict disease with a positive predictive value around 75% but a poor sensitivity. 89 Measurement of specific airway resistance (sRaw) using plethysmography could be useful. In epidemiological studies as early as age 3 years, sRaw differs between children with a history of wheezing and those without, 90 and higher sRaw at age 3 years is associated with subsequent persistence of wheezing. 91 sRaw seems to be also adequate to assess bronchodilator response in children. 92 However, in some studies, the use of sRaw in schoolchildren has not been adequate to diagnose asthma, because of high variability and huge overlap between healthy children and those with asthma.
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In summary, the value of plethysmography in asthma diagnosis is very limited, with sRaw having some role.
| Non-cooperative patients
Diagnosing asthma in preschool children is often challenging. 93 The demonstration of bronchial reversibility after administration of a bronchodilator helps clinicians to establish the appropriate treatment.
Unfortunately, in this age group, spirometry is often not applicable because results depend on effort and effective co-operation by patients. Therefore, non-invasive lung function measurements requiring only passive co-operation, while the patient is breathing at normal tidal volume, such as impulse oscillometry, the forced oscillation technique, and interrupter technique, have been proposed. 94 
Impulse oscillometry and forced oscillation technique
Impulse oscillometry (IOS) measures the resistance and resonance capacitance of the lungs, both at small and large airway level, performing measurements in a non-invasive, effort-independent manner during spontaneous breathing. The most relevant outcomes of IOS are R5, the resistance in small airways, R15 or higher, the resistance in larger airways and the low frequency integrated impedance reactance at R5. 94, 95 All these measurements can be compared to It has been shown that IOS provides effective measures of lung dysfunction in 4-year-old children at high risk for persistent asthma. 96 This was confirmed and extended in another study evaluating at this age range the effects of short-and long-acting bronchodilators. 97 More recent studies demonstrated the efficacy of IOS as an alternative to FEV1 in older asthmatic children. 98, 99 Interestingly, it has been shown that R5 but not FEV1 showed improvement in patients with persistent asthma after inhaled steroid treatment. 
The interrupter technique
The interrupter technique is able to detect changes in airway calibre. 104 The principles of the interrupter technique are that, during a sudden and rapid airflow interruption at the mouth, the alveolar and mouth pressure will equilibrate. The interrupter resistance (Rint) is defined as this pressure divided by the airflow measured immediately before interruption. 105 There are reference values for preschool children, which are difficult to compare being often obtained using different methods. The technique is able to measure the magnitude of changes in airway calibre after inhalation of a bronchodilator, but the cut-off value for a decrease in Rint beyond which a response may be considered clinically effective remains to be established. 94, 104, 105 To make the technique more reproducible and uniform between centres, a series of recommendations have been presented. 94 However, many issues remain to be clarified, particularly to establish the cut-off values beyond which a clinical response to bronchodilator could be considered clinically relevant.
Lung function tests in infants and asthma
Cohort studies have shown that those infants who develop asthma could have, prior to any respiratory illness, impaired lung function.
This premorbid condition has been described in different asthma phenotypes. [106] [107] [108] [109] If decreased lung function very early in life, or even in utero, plays any role in the development of asthma, we need to understand how and why this decrease is produced in order to design strategies to prevent it. Thus, it is important to study prenatal risk and protective factors (other than the known ones, such as prematurity and tobacco smoke exposure) related to lower lung function very early in life. And although we have some clues in infants born from high-risk mothers, 113 research should be extended to the whole population.
Inert gas washout for measurement of ventilation inhomogeneity
The majority of lung function tests measure flow; airway resistance; or lung volumes. While such measures are undeniably helpful, one of the greatest contributions to impaired respiratory function in asthma is the effectiveness of gas mixing or ventilation distribution. We know that ventilation distribution has some degree of heterogeneity in healthy individuals is more pronounced those with stable airways disease; and that this situation can lead to catastrophic shifts-in turn leading to hypoxaemia-during bronchoconstriction. 114 There is therefore increasing interest in the objective monitoring of ventilation heterogeneity in both stable and unstable asthma, and the most promising tools for this are inert gas washout tests.
These investigations rely upon measurement of exhaled inert gas (either nitrogen or a previously inhaled gas such as sulphur hexafluoride) during multiple breath or single breath washout (MBW or SBW). The former test usually employs tidal breathing and produces indices of overall ventilation heterogeneity such as the lung clearance index (LCI), or mechanism dependent indices such as S cond and S acin , which broadly measure conducting airway generated heterogeneity and more peripherally generated heterogeneity, respectively. 115 SBW usually employs a raised volume inspiration and expiration, and the phase III slope of the expiration is analysed.
Performing SBW using multiple inert gases of differing molecular weight and therefore diffusivity can provide additional information as to where in the airway tree changes in airway calibre are likely to be occurring. 116, 117 Calculation of the S cond and S acin indices from MBW has demonstrated that proximal conducting airways and more peripheral airways generate heterogeneity in subjects with asthma, and that both mechanisms are partly but not wholly reversed by bronchodilator. 115, 118, 119 Intriguingly, the degree of baseline heterogeneity appears to predict the severity of airway hyperresponsiveness in adults and children with asthma, [120] [121] [122] in a way that differs from subjects with COPD. 123 One possible explanation is that baseline heterogeneity is predictive of airway closure during bronchoconstriction. 114, 124 Further studies have identified relationships between heterogeneity and symptom control 125 ; clinical stability 118 ; and response to inhaled corticosteroids. 126 The link between heterogeneity and inflammation, as measured by exhaled nitric oxide, is not clear, like with most lung function tests. 121, 122, 127 There are limited data relating heterogeneity to asthma phenotype, although one study in children with preschool wheeze has identified S cond as an excellent discriminator between the episodic viral wheeze and multitrigger wheeze phenotypes, 128 although those phenotypes have not been shown to be very stable over time. 129 It is noted that the majority of studies utilizing MBW have employed the S cond and S acin indices. Global indices such as LCI are widely used in the study of CF lung disease and in bronchopulmonary dysplasia, but how LCI relates to S cond and S acin in asthma is not well understood. 128, 130, 131 The SBW test is quicker and more straightforward to perform and interpret than MBW, and some of the earliest studies investigating ventilation heterogeneity in asthma and COPD used this method. [132] [133] [134] These studies identified links between asthma diagnosis and severity and the Phase III slope from SBW. More recent studies have confirmed these findings 135 and have utilized multiple gases to localize presumed bronchoconstriction. 116, 117, 136 The field is new, and not yet well understood. However, the use of MBW is in the process of transforming the monitoring and care of early/mild CF lung disease, and the promising early data in subjects with asthma should not be ignored. It is possible that inert gas washout tests could prove to have advantages over more traditional lung function tests in asthma monitoring, particularly given that ventilation heterogeneity is known to be present at baseline, and to lead to dramatic changes in ventilation distribution during bronchoconstriction. An additional, crucial advantage is that most inert gas washout measurements can be collected during tidal breathing and can therefore be performed in infants; preschool children; and older subjects who are unable to co-operate with more traditional lung function tests.
At present, the MBW technique is too complex and time-consuming to be employed in routine asthma monitoring but will continue to be researched to better understand asthma phenotyping and physiology. In the longer term, the development of tidal breathing SBW, possibly utilizing multiple inert gases, could become a valuable clinical tool. There is more than one approach to develop such a test, but it is noted that a multiple gas method has already been used to identify peripherally generated heterogeneity in children with mild asthma symptoms and normal spirometry. 136 
| Bronchodilation
The diagnosis of asthma should be based on the history of characteristic symptom patterns and evidence of variable airflow limitation. 83 As and supports the diagnosis of asthma. 83, 137 There is no consensus about the drug, dose or mode of administering the bronchodilator in the lung function laboratory. Current guidelines recommend inhalation of 100-400 lg (children) and 200-400 lg (adults) salbutamol or equivalent. 83 As an alternative to measuring the immediate response to a bronchodilator in the lung function laboratory, it is also recommended by some guidelines to test the response to 2-8 weeks of a therapeutic trial with inhaled corticosteroids (ICS). Also, there is no clear consensus about which degree of lung function improvement constitutes significant reversibility in subjects with airflow obstruction. 137 There is as yet no consensus on how a bronchodilator response should be expressed (percent of initial spirometric value, or percent of predicted value, or absolute change), and which variables should be used (FEV1, FVC, PEF). These differences are due to the heterogeneity of study designs and results, and also due to different interpretations of the outcomes of these studies that have been conducted in the general population and in patient populations (studies referenced by 137 ). Also, the bronchodilator response tends to increase with decreasing baseline FEV1. 138 So, upon establishment of a generally applicable guideline, decisions will always be well-founded, but nonetheless, the definition of a universal cut-off GARCIA-MARCOS ET AL.
| 111 level for a "positive" bronchodilator response will finally be arbitrary.
Increments of lung function parameters of <8% are likely to lie within the range of measurement variability. 137, 139, 140 The recent 2017 GINA guidelines indicate the following criteria for making the diagnosis of asthma: for adults, an increase in FEV1 of >12% and >200 mL from baseline, and for children, an increase in FEV1 > 12% predicted. The ATS/ERS task force on standardization of lung function testing considers post-bronchodilator FEV1 or FVC > 12% and 200 mL compared with baseline as "significant" bronchodilation. 137 Even though international recommendations regarding reversibility testing do differ in various aspects, knowledge of the ATS/ERS task force suggestions appears useful as this proposal has been set up to help minimize differences within and between laboratories.
Beyond numerical criteria, it also appears useful in clinical practice to judge and compare the shapes of the flow-volume curves before and after bronchodilator inhalation.
A large worldwide study on the bronchodilator response in adult healthy general populations recently reaffirmed the 12% criterion 141 which approximates the 95th percentile for the percentage change in FEV1 after bronchodilator inhalation in general population studies mainly consisting of adults. 142 Still, the recommendations of the ATS/ERS task force have very recently been a subject of animated scientific debate. [143] [144] [145] [146] In any case, sensitivity and specificity of the bronchodilator response for the diagnosis of asthma are limited. One major problem in judging reversibility tests in the diagnosis of adult asthma is the fact that there is also a significant bronchodilator response in COPD. 147 Patients with asthma may tend to show a larger increase in flow and volume after inhalation of a bronchodilator than COPD patients, 137 and a > 400 mL improvement in FEV1 in response to a bronchodilator is considered to strongly suggest underlying asthma. 83 However, the response to a bronchodilator has never been shown to add to the differential diagnosis, and the Global Initiative for Chronic Obstructive Lung Disease recommends that the degree to which airflow is reversible should not be used as a criterion in making the differential diagnosis between asthma and COPD. 148 In children, diseases other than asthma may be associated with significant bronchodilator responses, such as allergic rhinitis and bronchopulmonary dysplasia. 149 On the other hand, also in children, an absent response to bronchodilators does not exclude asthma. 150 If the bronchodilator test is positive, it has been shown in children that this is predictive of a good response to ICS. 151 However, as most children with asthma have baseline FEV1 within the normal range, 152 the diagnostic value of bronchodilator responses during stable disease may often be limited in this age group. Different cutoff values have been proposed for the paediatric age group to increase sensitivity and specificity of bronchodilator response tests.
The most recent of these studies on the validity of current criteria of a significant bronchodilator response included a large cohort of 1041 children with mild-to-moderate asthma from the US Childhood Asthma Management Program (CAMP) that were compared to 250 control subjects. Here, the conventional "adult" cut-off of 12% improvement in absolute FEV1 was associated with a good specificity for asthma diagnosis of 89.5%, but with a poor sensitivity of 35.6%. 153 This poor sensitivity may be due to the fact that only a minority of CAMP children had a baseline FEV1 of <80% predicted.
Even though a cut-off of 8% resulted in a better sensitivity (54.4%), the authors do not recommend to choose a lower specific general cut-off criterion, given the variability of this test in children.
To summarize, the bronchodilator response test is one of the pieces in the mosaic of diagnosing asthma, along with a characteris- have the higher accuracy to make a correct diagnosis in mild-tomoderate asthma. 158 Methacholine or histamine bronchial responsiveness is mainly seen as a marker of airway wall remodelling or intrinsic smooth muscle abnormality. 159 The role of eosinophilic inflammation in bronchial hyperresponsiveness, though not absent, is limited. 160 Indirect challenges such as mannitol or exercise challenge are complementary to direct agent challenges and may reflect more accurately the underlying airway inflammation. 161 Direct challenge tests are sensitive and better to exclude asthma, while indirect challenge tests are seen as more specific and better to confirm the presence of the condition. 162 The level of bronchial hyperresponsiveness to indirect agents is highly and rapidly sensitive to ICS treatment. 161 The effect of ICS on responsiveness to histamine and methacholine is much less impressive but sustained decrease over time was observed with continuous treatment. 159 Some study suggests that looking at FVC rather than FEV1 during a methacholine challenge may more informative on disease severity. 163 The slope dose-response curve to methacholine was shown to correlate to ACQ in a population of unselected asthmatic patients, the stronger the responsiveness the poorer the asthma control. 164 The utility to include bronchial hyperresponsiveness (BHR) as a parameter to adjust asthma treatment has been less studied than with FeNO. There is one study that showed that monitoring methacholine responsiveness using PC20M to adjust the dose of ICS improved asthma control. 165 Although another study could not find any difference in terms of asthma-free days, however, adjustment by BHR produced a better outcome with respect to pre-bronchodilator FEV1 in allergic asthmatic children. 166 Most of asthmatics are seen in the primary care setting. As asthma diagnosis is difficult in primary care and often leads to overdiagnosis 167, 168 and wrong treatment allocation, it is an urgent need to find a convenient test for assessing bronchial hyperresponsiveness that may be applicable for general practitioners, that is easy to learn and administer and not too time-consuming. Mannitol challenge might do it, but it has to be demonstrated in large-scale study in general practice. 169 
| Asthma prediction
Although some previous papers 170 looked for early markers for future asthma, the first index built on a prospective cohort of newborn children was the Asthma Predictive Index (API indicators were used to use a loose and a stringent index which included major and minor criteria. These indices were used to predict asthma at the age 6, 8, 11 and 13 years. API was modified to be used as an inclusion criteria tool in the Prevention of Early Asthma in Kids (PEAK) study as an expert opinion: one minor criterion (recurrent nasal symptoms) was substituted for two (sensitization to aeroallergens and food allergy). 171 The Isle of Wight score 172 predicted persistence of wheeze at age 10 of children who wheezed at 1, 2 and 4 years of life (see Table 3 for specific items of the score, range 0-4). A cut-off point of ≥3 was found to be the highest discriminative.
Another predictive score was developed from the data of a nested case-control study of 449 children included in the Environmental and Childhood Asthma birth cohort (ECA). 4, 173 Children with recurrent [≥2 episodes of or ≥4 weeks (persistent)] doctor confirmed bronchial obstruction by their second birthday were cases. The authors built a severity score (0-12 points, see Table 3 for items in the score) and used a cut-off of >5 to predict asthma at age 10.
The PIAMA (Prevention and Incidence of asthma and Mite Allergy) score 174 was calculated from the findings of this birth cohort by the age of 8 years. Several markers found in children who had wheeze and/or cough at night without colds during the previous 12 months at ages 1 through 4 years were used to build a score (0-55 points) in order to predict asthma at age 8 years. A cut-off value of ≥20 was found to be the best in diagnostic performance.
The latest predictive model published is the one from the Leicestershire Respiratory Cohort Studies, 175 which included children followed from birth who had at least a healthcare visit between ages 1 and 3 years for respiratory problems plus wheeze and/or cough without a cold and/or cough at night. The presence of wheeze plus asthma medication during the previous 12 months was used as asthma case definition at 6-8 years of age.
Although those prediction tools are easy to apply their diagnostic power needs to be improved: the best Youden's index does not reach even 0.5, and although the specificity value is quite acceptable, the sensitivity one is quite low. Performance of API and PIAMA scores in subsequent (validation) studies did not improve, producing relatively low rates of false positives (8%-67%) but quite high rates of false negatives (29%-80%). 174, [176] [177] [178] An additional limitation, which has not been fully addressed, is the exact definition of the dependent (outcome) variable used to However, and based on the data in Table 3 , there seem to be 2 different areas which might determine future asthma when present in infants or preschool children: allergy and severity of wheezing episodes.
Other attempts to build prediction indexes/scores to predict asthma in adulthood from data in childhood have reached to similar conclusions. 180 Some authors have suggested that biological markers might predict asthma. Among those biomarkers which might have some usefulness are as follows: eosinophils, ECP, specific IgE, filaggrin mutations, Th2 interleukins, FeNO, EBC characteristics and composition and, of course, genetics in the form of polygenic risk and genetic risk scores. [181] [182] [183] [184] To use prediction indices as a generalized tool, their predictive power needs to be improved. The current evidence suggests that a tool based only on clinical data is limited in its predictive capacity;
and that adding one or several biomarkers could be helpful. Which biomarker(s) is(are) more useful remains to be elucidated; and might be a research priority.
There are probably 4 fields in which the new predicting tools 
| CONSENSUS EXERCISE
The exercise included two Delphi rounds previous to a summarizing workshop in which the information obtained in the Delphi rounds was shared and the 3 most important topics among those obtaining a mean score of 3 or more in the Delphi rounds were chosen and ranked.
| Delphi exercises (1st and 2nd rounds)
To reach an agreement on the most important diagnostic tools for future research investment, a list of statements extracted from the review, 21 statements (Table 4) (Table 4 ).
| Summarizing workshop
To better refine and contextualize the priorities produced from the ranked from highest to lowest, as shown in Table 5 .
| CONCLUSION S
Research on the prediction of asthma in preschool age with reasonable accuracy and how to integrate the new biological markers in the diagnosis and monitoring of asthma should be the two main research areas towards which the economic effort should be addressed. A third area of importance is the measurement of exhaled volatile organic (VOCs) compounds. If Volatilome is contemplated as a new biological marker, the importance of its measurement would be probably enhanced.
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